TAS-102 plus bevacizumab in metastatic colorectal cancer

被引：0
|
作者：
Colloca, Giuseppe A. [1 ]
Venturino, Antonella [1 ]
机构：
[1] Osped Civile Sanremo, Dept Oncol, I-18038 San Remo, Italy
来源：
LANCET ONCOLOGY | 2020年 / 21卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E226 / E226
页数：1
相关论文
共 50 条
  • [41] Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer: a Danish randomized trial
    Pfeiffer, P.
    Yilmaz, M.
    Moller, S.
    Zitnjak, D.
    Maltha, L.
    Krogh, M.
    Winther, S.
    Petersen, L.
    Hejlersen, F.
    Thomsen, K.
    Qvortrup, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO)
    Boland, Patrick M.
    Mukherjee, Sarbajit
    Imanirad, Iman
    Vijayvergia, Namrata
    Cohen, Seth D.
    Gupta, Medhavi
    Iyer, Renuka V.
    Chatley, Sarah
    Cahill, Beth
    Vadehra, Deepak
    Attwood, Kristopher
    Hochster, Howard S.
    Fountzilas, Christos
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer
    Zhang, Jing
    Yang, Wenwei
    Liu, Junbao
    Wang, Nan
    Ren, Zhaoying
    Yang, Tingting
    Xie, Gongli
    Wu, Guifu
    Sun, Yongkun
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (04) : 454 - 461
  • [44] Prophylactic use of pegfilgrastim enables the management of severe neutropenia without dose delays in patients with metastatic colorectal cancer treated with TAS-102 plus bevacizumab
    Tamaki, Sawako
    Ishikawa, Hideki
    Suzuki, Koichi
    Kimura, Yasuaki
    Maemoto, Ryo
    Abe, Iku
    Endo, Yuhei
    Kakizawa, Nao
    Watanabe, Fumiaki
    Futsuhara, Kazushige
    Saito, Masaaki
    Tsujinaka, Shingo
    Miyakura, Yasuyuki
    Rikiyama, Toshiki
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (05)
  • [45] Colorectal Cancer TAS-102 effective with refractory Recurrence
    Franke, Katharina
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2015, 53 (10): : 1144 - 1144
  • [46] TAS-102 in refractory colorectal cancer: caution is needed
    Sobrero, Alberto
    LANCET ONCOLOGY, 2012, 13 (10): : 959 - 961
  • [47] Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Johanna C. Bendell
    Lee S. Rosen
    Robert J. Mayer
    Jonathan W. Goldman
    Jeffrey R. Infante
    Fabio Benedetti
    Donghu Lin
    Hirokazu Mizuguchi
    Christopher Zergebel
    Manish R. Patel
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 925 - 932
  • [48] Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
    Qi Zhang
    Qianqian Wang
    Xicheng Wang
    Jian Li
    Lin Shen
    Zhi Peng
    International Journal of Colorectal Disease, 2020, 35 : 295 - 306
  • [49] Hospitalizations and clinical outcome in metastatic colorectal cancer during regorafenib or TAS-102 therapy
    Huemer, F.
    Piringer, G.
    Schlintl, V.
    Hackl, H.
    Rinnerthaler, G.
    Thaler, J.
    Greil, R.
    Weiss, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 128 - 128
  • [50] Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
    Chen, Duke
    Wu, Yu-Shen
    Lin, Huapeng
    Wang, Yihan
    Li, Longhao
    Zhang, Tao
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 2915 - 2924
12345